Children's Hospital at Westmead

The Children’s Hospital at Westmead is one of the largest paediatric cancer centres in the Southern Hemisphere, caring for children and adolescents from across New South Wales and beyond.

Embedded within a major research and education precinct, the site plays a leading role in clinical trials and translational research through ANZCHOG partnerships.

Recruiting Trials

Open

Not Applicable

CIRCAA

Cancer Information Registry for Children and Adolescents in Australia

No limit

Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours

Open

Phase 2

CONNECT-TarGeT ArmA

Phase II Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT

12 months

39 years

N/A

CNS tumours

Preparing to Open

Phase 2

CONNECT2110

A Phase II Trial of ACT001 in Children and Adolescents with Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

12 months

39 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

Phase 1/2

DART

Phase I/II Trial of Deflexifol for Refractory or Recurrent Paediatric CNS Tumours

12 months

21 years

CNS tumours

Open

Phase 1/2

FaR-RMS (RG_17-247)

An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

No limit

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Westmead Adult Hospital

Soft tissue and bone tumours

Open

Phase 2/3

Glo-BNHL (RG_21-124)

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

≤ 25 years

Queensland Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Haematolymphoid disorders

Open

Phase 1/2

INFORM2 NivEnt

Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

2 years

21 years

Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Open

Phase 3

Met Med Can

Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain tumour.

7 years

21 years

John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Sir Charles Gardiner Hospital

CNS tumours

Open

NB-SCI

Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)

< 18 years

Peripheral neuroblastic tumours

Open

Phase 1/2

OPTIMISE Appendix A

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours

1 year

21 years

Preparing to Open

Phase 1/2

PaedNeoVax (ANZCHOG2511)

Multicentre, investigator-initiated phase I/II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study

6 months

25 years

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 1

PNOC019

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)

6 months

25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 2

PNOC022

A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

2 years

39 years

CNS tumours

Open

Phase 2

PNOC029

Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

1 year

39 years

John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 2/3

rEECur (RG_13-277)

International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

≥ 2 years (no upper limit)

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital, Sir Charles Gardiner Hospital

Soft tissue and bone tumours

Preparing to Open

Phase 2

SJiMB21

Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

< 60 months

Queensland Children’s Hospital, John Hunter Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

Phase 2

TarGeT-A

Phase II Study of Ribociclib and Everolimus Following Radiotherapy in paediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT

12 months

39 years

CNS tumours

Open

Phase 2

TarGeT-D

Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in paediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations

12 years

39 years

CNS tumours

Preparing to Open

Phase 1

TarGeT-L

A Pilot Study of Lorlatinib for Treatment of Children with Newly Diagnosed High-Grade Glioma with ROS-1 and ALK Fusion

1 year

21 years

CNS tumours

Open

TarGeT-SCR

Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG) – SCREENING PROTOCOL

12 months

39 years

CNS tumours

Preparing to Open

U-R-Immune Glioma

A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients with Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

12 months

25 years

CNS tumours

Open

Phase 1

VICTORY

A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in paediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas

≤ 25 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

ZERO2

Precision Medicine for Every Child With Cancer

< 25 years

Open

Phase 2

AALL1821

Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients

1 year

31 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 3

AAML1531

Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

91 days

3 years

Sydney Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 1/2

ACNS1821

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed paediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

12 months

21 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 2

ACNS2021

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

3 years

29 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

Phase 2

ACNS2321

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patient with Central Nervous System Germinomas

3 years

29 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

Brain and Spinal (Central Nervous System) Tumours

Open

ACOR

Australian Cardio-Oncology Registry

<35 years

John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours

Open

Phase 3

AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk paediatric and Adult Patients with Germ Cell Tumors

Various depending on risk group & consult protocol

Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Germ Cell Tumours

Open

Phase 3

ALLELE (ATA129-EBV-302)

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy

No limit

Royal Children’s Hospital, Women’s and Children’s Hospital, Children’s Hospital at Westmead

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 2

ANBL1821

A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma

>1 year

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Neuroblastoma and Ganglioneuroblastoma

Open

Phase 2

ANHL2121

Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

189 days

22 years

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 3

AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

<50 years

John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Soft Tissue and Bone Tumours (Sarcoma)

Open

Phase 2/3

AOST2032

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

<40 years

Soft Tissue and Bone Tumours (Sarcoma)

Open

Phase 3

APAL2020D

A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

29 days

21 years

Queensland Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

Phase 1/2

APAL2020SC

paediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

<22 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Leukaemia / Lymphoma / Blood Disorders

Open

APEC14B1

Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study

<25 years

Open

Phase 2

ARAR2221

A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)

<21 years

John Hunter Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Head and neck tumours

Open

Phase 2

AREN1921

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

<30 years

Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Renal and male genital tumours

Open

Phase 2

ARET2121

Intravitreal Melphalan for Intraocular Retinoblastoma

<18 years

Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Eye tumours

Open

Phase 3

ARST2031

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

<50 years

Queensland Children’s Hospital, Children’s Hospital at Westmead

Soft tissue and bone tumours

Open

Phase 3

ARST2032

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

<21 years

Sydney Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital

Soft tissue and bone tumours

Open

Phase 3

ASCT2031

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)

6 months

21 years

Perth Children’s Hospital, Children’s Hospital at Westmead

Haematolymphoid disorders

Open

Phase 1

CARTpaedST

Developing genetically modified TCells for the treatment of paediatric solid tumours

<18 years

Children’s Hospital at Westmead

Open

Phase 1

D0816C00025

A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours

<18 years

Queensland Children’s Hospital, Monash Health Clayton, Children’s Hospital at Westmead

Open

Phase 2

DAY101-001 (FIREFLY)

A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in paediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma

6 months

25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Women’s and Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 3

Firefly-2

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With paediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

<25 years

Sydney Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital

CNS tumours

Open

Phase 4

HeadStart4

Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue

<10 years

Children’s Hospital at Westmead, Christchurch Hospital

CNS tumours

Closed to Recruitment

Phase 1

I3Y-MC-JPCS

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in paediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in paediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)

<21 years

Perth Children’s Hospital, Children’s Hospital at Westmead

Open

Phase 2

I3Y-MC-JPEH

Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy

<20 years

Queensland Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

Phase 1/2

iMATRIX (GO42286)

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in paediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available

<17 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

Open

Levi's CATCH

LEVERAGING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS FOR CHILDREN WITH DIFFUSE MIDLINE GLIOMA (LEVI’S-CATCH)

<21 years

Sydney Children’s Hospital, Children’s Hospital at Westmead

CNS tumours

Open

LIBIO

Liquid biopsies for molecular monitoring of paediatric solid tumours

<25 years

Children’s Hospital at Westmead

Open

Phase 1

M20-429

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in paediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms

1 year

26 years

Perth Children’s Hospital, Children’s Hospital at Westmead

Haematolymphoid disorders

Open

Phase 1

R3ACT Fungal

A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation

1 year

80 years

Children’s Hospital at Westmead

Haematolymphoid disorders

Open

T2018-001

A retrospective cohort study of response and survival in paediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy

<21 years

Royal Children’s Hospital, Children’s Hospital at Westmead

Haematolymphoid disorders

Open

Phase 1

T2020-006

A Phase I Study of Tagraxofusp With or Without Chemotherapy in paediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies

1 year

21 years

Children’s Hospital at Westmead

Haematolymphoid disorders

Open

Phase 1/2

TPX-0005-07

A phase 1/2, open-label safety, tolerability, pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations

<25 years

Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead

ANZCHOG Hospital Sites

Australia & New Zealand · 11 Sites

About

The peak professional body for childhood cancer across Australia and New Zealand.

Menu

Menu

Considering a clinical trial for a child: A caregiver’s view

Should my child participate in a clinical trial

Menu

Getting to know CoACT in Brain Cancer Awareness Month

Australian Government invests $14 million in ANZCHOG-led childhood brain cancer initiative

Menu

Innovate, Integrate, Inspire: Elevating Supportive Care in Paediatric Haematology and Oncology

Menu

40 Years, 40 People, 40 Questions

Menu

1 SEPT

- 31 SEPT

Better Challenge

Children's Hospital at Westmead

Open Trials

Get Directions

Contact

Recruiting Trials

CIRCAA

CONNECT-TarGeT ArmA

CONNECT2110

DART

FaR-RMS (RG_17-247)

Glo-BNHL (RG_21-124)

INFORM2 NivEnt

Met Med Can

NB-SCI

OPTIMISE Appendix A

PaedNeoVax (ANZCHOG2511)

PNOC019

PNOC022

PNOC029

rEECur (RG_13-277)

SJiMB21

TarGeT-A

TarGeT-D

TarGeT-L

TarGeT-SCR

U-R-Immune Glioma

VICTORY

ZERO2

AALL1821

AAML1531

ACNS1821

ACNS2021

ACNS2321

ACOR

AGCT1531

ALLELE (ATA129-EBV-302)

ANBL1821

ANHL2121

AOST2031

AOST2032

APAL2020D

APAL2020SC

APEC14B1

ARAR2221

AREN1921

ARET2121

ARST2031

ARST2032

ASCT2031

CARTpaedST

D0816C00025

DAY101-001 (FIREFLY)

Firefly-2

HeadStart4

I3Y-MC-JPCS

I3Y-MC-JPEH

iMATRIX (GO42286)

Levi's CATCH

LIBIO

M20-429

R3ACT Fungal

T2018-001

T2020-006

 Innovate, Integrate, Inspire:   Elevating Supportive Care in Paediatric Haematology and Oncology  